Additional effect of statin to PegIFN/Ribavirin treatment in chronic hepatitis C patients

Additional effect of statin to PegIFN/Ribavirin treatment in chronic hepatitis C patients - PEG-IFN alfa2b + Ribavirin combination therapy + statin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003468

Enrollment

400

Registered

2010-04-09

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C of genotype1 in high viral load(&gt

Interventions

All patients receive PegIFN alfa2b and Ribavirin and statin . Any type of statins are available to be used and each drug is used according to the package insert. The duration of treatment is basicall

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Positive for antibody to HCV 2)HCV RNA of genotype is 1b 3)High HCV RNA levels (>=5.0 logIU/mL) 4)Without HCC

Exclusion criteria

Exclusion criteria: 1) Used Ribavirin in previous treatments 2) Pregnant , possibly pregnant or lactating women 3) Patients with severe heart disease 4) Chronic kidney failure or creatinine clearance of <=50 mL/min 5) Current or history of severe psychiatric disorder 6) Autoimmune hepatitis 7) Intolerance to statin

Design outcomes

Primary

Measure	Time frame
SVR rate	—

Countries

Japan

Contacts

Public ContactTakayoshi Ito

Showa University School of Medicine Department of Gastroenterology

tito@med.showa-u.ac.jp03-3784-8535

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026